Glaxosmithkline Plc Adr Stock Today
| GSK Stock | USD 40.50 0.16 0.39% |
Performance4 of 100
| Odds Of DistressLess than 11
|
GlaxoSmithKline PLC is selling for 40.50 as of the 16th of April 2024. This is a -0.39 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 40.44. GlaxoSmithKline PLC has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for GlaxoSmithKline PLC ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of July 2023 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of July 1986 | Category Healthcare | Classification Health Care |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. The company has 2.04 B outstanding shares of which 4.83 M shares are currently shorted by investors with about 1.83 days to cover. More on GlaxoSmithKline PLC ADR
Moving together with GlaxoSmithKline Stock
| 0.71 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.64 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
Moving against GlaxoSmithKline Stock
| 0.73 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.72 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.58 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
| 0.49 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 24th of April 2024
GlaxoSmithKline Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. GlaxoSmithKline PLC's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding GlaxoSmithKline PLC or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Emma Walmsley | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering GlaxoSmithKline PLC report their recommendations after researching GlaxoSmithKline PLC's financial statements, talking to executives and customers, or listening in on GlaxoSmithKline PLC's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering GlaxoSmithKline PLC ADR. The GlaxoSmithKline consensus assessment is calculated by taking the average forecast from all of the analysts covering GlaxoSmithKline PLC. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the measurements of operating efficiency obtained from GlaxoSmithKline PLC's historical financial statements, GlaxoSmithKline PLC ADR is doing better financially then in previous quarter. It has a moderate probability of reporting better financial numbers in May. Financial strength of GlaxoSmithKline PLC ADR is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GlaxoSmithKline PLC's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to GlaxoSmithKline PLC's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GlaxoSmithKline PLC's financial leverage. It provides some insight into what part of GlaxoSmithKline PLC's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GlaxoSmithKline PLC ADR (GSK) is traded on New York Stock Exchange in USA. It is located in 980 Great West Road, Brentford, United Kingdom, TW8 9GS and employs 70,212 people. GlaxoSmithKline PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 83.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. GlaxoSmithKline PLC ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2.04 B outstanding shares of which 4.83 M shares are currently shorted by investors with about 1.83 days to cover.
GlaxoSmithKline PLC ADR has about 3.72 B in cash with 6.35 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32.
Check GlaxoSmithKline PLC Probability Of Bankruptcy
Ownership AllocationGlaxoSmithKline PLC secures a total of 2.04 Billion outstanding shares. Roughly 86.0 (percent) of GlaxoSmithKline PLC outstanding shares are held by general public with 14.4 pct. by outside corporations. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check GlaxoSmithKline Ownership Details
GlaxoSmithKline Stock Price Odds Analysis
Proceeding from a normal probability distribution, the odds of GlaxoSmithKline PLC jumping above the current price in 90 days from now is about 70.13%. The GlaxoSmithKline PLC ADR probability density function shows the probability of GlaxoSmithKline PLC stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon GlaxoSmithKline PLC has a beta of 0.4384. This usually indicates as returns on the market go up, GlaxoSmithKline PLC average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding GlaxoSmithKline PLC ADR will be expected to be much smaller as well. Additionally, glaxoSmithKline PLC ADR has an alpha of 0.005, implying that it can generate a 0.005012 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of GlaxoSmithKline PLC to move above the current price in 90 days from now is about 70.13 (This GlaxoSmithKline PLC ADR probability density function shows the probability of GlaxoSmithKline Stock to fall within a particular range of prices over 90 days) .
GlaxoSmithKline Stock Institutional Holders
Institutional Holdings refers to the ownership stake in GlaxoSmithKline PLC that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of GlaxoSmithKline PLC's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing GlaxoSmithKline PLC's value.| Instituion | Recorded On | Shares | |
| Arrowstreet Capital Limited Partnership | 2023-12-31 | 4.8 M | |
| Mondrian Investment Partners Ltd | 2023-12-31 | 4 M | |
| Provident Trust Company | 2023-12-31 | 3.7 M | |
| Equity Investment Corp | 2023-12-31 | 3.2 M | |
| Eversept Partners, Llc | 2023-12-31 | 3 M | |
| Renaissance Technologies Corp | 2023-12-31 | 2.8 M | |
| Hotchkis & Wiley Capital Management Llc | 2023-12-31 | 2.7 M | |
| Hsbc Holdings Plc | 2023-12-31 | 2.5 M | |
| Wells Fargo & Co | 2023-12-31 | 2.5 M | |
| Dodge & Cox | 2023-12-31 | 69 M | |
| Fmr Inc | 2023-12-31 | 19.4 M |
GlaxoSmithKline PLC Historical Income Statement
GlaxoSmithKline PLC ADR Income Statement is one of the three primary financial statements used for reporting GlaxoSmithKline's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of GlaxoSmithKline PLC ADR revenue and expense. GlaxoSmithKline PLC Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, GlaxoSmithKline PLC's Extraordinary Items is quite stable compared to the past year. Reconciled Depreciation is expected to rise to about 1.7 B this year, although the value of Total Revenue will most likely fall to about 19.9 B. View More FundamentalsGlaxoSmithKline Stock Against Markets
Picking the right benchmark for GlaxoSmithKline PLC stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in GlaxoSmithKline PLC stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for GlaxoSmithKline PLC is critical whether you are bullish or bearish towards GlaxoSmithKline PLC ADR at a given time. Please also check how GlaxoSmithKline PLC's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in GlaxoSmithKline PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
GlaxoSmithKline PLC Corporate Directors
GlaxoSmithKline PLC corporate directors refer to members of a GlaxoSmithKline PLC board of directors. The board of directors generally takes responsibility for the GlaxoSmithKline PLC's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of GlaxoSmithKline PLC's board members must vote for the resolution. The GlaxoSmithKline PLC board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Vindi Banga | Senior Independent Non-Executive Director | Profile | |
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Daniel Podolsky | Non-Executive Independent Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile |
How to buy GlaxoSmithKline Stock?
Before investing in GlaxoSmithKline PLC, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in GlaxoSmithKline PLC. To buy GlaxoSmithKline PLC stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of GlaxoSmithKline PLC. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase GlaxoSmithKline PLC stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located GlaxoSmithKline PLC ADR stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased GlaxoSmithKline PLC ADR stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as GlaxoSmithKline PLC ADR, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy GlaxoSmithKline Stock please use our How to Invest in GlaxoSmithKline PLC guide.
Already Invested in GlaxoSmithKline PLC ADR?
The danger of trading GlaxoSmithKline PLC ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of GlaxoSmithKline PLC is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than GlaxoSmithKline PLC. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile GlaxoSmithKline PLC ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 3 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.